Breast cancer research program
Ended Awarded Last action
- Contract number
- HT942525FE055
- Awardee
-
Leidos, Inc. UEI QLNMVC12KWY3 Part of Leidos Holdings, Inc.
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $270,150
Award facts
- Contract value 100% obligated
- $270,149.65 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Reston, VA 20190, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Funding Only Action | $85,701 | |
| Original award | $184,449 |
About this award
Leidos, Inc. was awarded a delivery order valued at $270,149.65 on December 2, 2025, under a cost-plus-fixed-fee contract to support the Defense Health Agency's Breast Cancer Research Program. The work will be performed in Reston, Virginia, with an ultimate completion date of May 15, 2026. This delivery order was issued without a set-aside designation, reflecting Leidos' status as an established large contractor. The Defense Health Agency, operating under the Department of Defense, administers the congressionally directed medical research programs that fund innovative cancer research initiatives, and Leidos brings substantial experience in providing administrative and technical support services for such medical research efforts across multiple disease areas.
This award represents a task order issued under Leidos' existing indefinite delivery vehicle relationships with the Defense Health Agency. As a major federal contractor with extensive experience supporting defense health initiatives, Leidos is well-positioned to deliver the comprehensive administrative and technical services required for cancer research program management. The company's portfolio includes similar work supporting congressionally directed medical research programs, including research across multiple cancer types and other disease areas, making this breast cancer research support award consistent with Leidos' established capabilities in the defense health sector.
Quick answers
Who was awarded contract HT942525FE055?
HT942525FE055 was awarded to Leidos, Inc. by Defense Health Agency (Department of Defense) on December 2, 2025.
How much is contract HT942525FE055 worth?
The government has obligated $270,150 on HT942525FE055.
Is contract HT942525FE055 an order under another contract?
Yes. HT942525FE055 is a delivery order under HT942523D0002, an indefinite delivery contract.
Was contract HT942525FE055 competed?
The extent of competition for HT942525FE055 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award